


**Amendments to the Claims:**

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1-29 (canceled).

30. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (I):



(I)

wherein: X is -CHR<sub>3</sub>-, -CHR<sub>3</sub>-alkyl-, or -CHR<sub>3</sub>-alkenyl-;

Z is -S-, -SO-, or -SO<sub>2</sub>-;

R<sub>1</sub> is selected from the group consisting of:

-alkyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkenyl;

-R<sub>4</sub>-aryl;

-R<sub>4</sub>-heteroaryl;

-R<sub>4</sub>-heterocyclyl;

R<sub>2</sub> is selected from the group consisting of:

-hydrogen;  
-alkyl;  
-alkenyl;  
-aryl;  
-heteroaryl;  
-heterocyclyl;  
-alkyl-Y-alkyl;  
-alkyl-Y-alkenyl;  
-alkyl-Y-aryl; and  
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;  
-halogen;  
-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-C<sub>1-10</sub> alkyl;  
-CO-O-C<sub>1-10</sub> alkyl;  
-N<sub>3</sub>;  
-aryl;  
-heteroaryl;  
-heterocyclyl;  
-CO-aryl; and  
-CO-heteroaryl;

each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl;

R<sub>4</sub> is alkyl or alkenyl;

Y is -O- or -S(O)<sub>0-2</sub>;


n is 0; and

each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

31-38 (canceled)

39. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (II):



(II)

wherein: X is  $-CHR_3-$ ,  $-CHR_3$ -alkyl-, or  $-CHR_3$ -alkenyl-;

Z is  $-S-$ ,  $-SO-$ , or  $-SO_2-$ ;

$R_1$  is selected from the group consisting of:

- alkyl;
- aryl;
- heteroaryl;
- heterocyclyl;
- alkenyl;
- $-R_4$ -aryl;
- $-R_4$ -heteroaryl; and
- $-R_4$ -heterocyclyl;

$R_2$  is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- heteroaryl;

-heterocyclyl;  
-alkyl-Y-alkyl;  
-alkyl-Y-alkenyl;  
-alkyl-Y-aryl; and  
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;  
-halogen;  
-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-C<sub>1-10</sub> alkyl;  
-CO-O-C<sub>1-10</sub> alkyl;  
-N<sub>3</sub>;  
-aryl;  
-heteroaryl;  
-heterocyclyl;  
-CO-aryl; and  
-CO-heteroaryl;

each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl;

R<sub>4</sub> is alkyl or alkenyl;

Y is -O- or -S(O)<sub>0-2</sub>-;

n is 0; and

each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

40-43 (canceled)

44. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound selected from the group consisting of:

1-[5-(methylsulfonyl)pentyl]-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[3-(methylthio)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[3-(methylsulfonyl)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-[3-(methylthio)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-[3-(methylsulfonyl)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[4-(methylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[4-(methylsulfinyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-[4-(methylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-[4-(methylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[4-(methylsulfonyl)butyl]-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[4-(methylsulfinyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[2-(methylthio)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[2-(methylsulfonyl)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[4-(methylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-[2-(methylsulfonyl)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[2-(methylsulfonyl)ethyl]-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-{4-[(2,4-difluorophenyl)thio]butyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-{4-[(2,4-difluorophenyl)sulfonyl]butyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[4-(ethylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-butyl-1-{4-[(1,1-dimethylethyl)thio]butyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-butyl-1-{4-[(4-fluorophenyl)thio]butyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-{4-[(4-fluorophenyl)sulfonyl]butyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-{4-[(1-methylethyl)thio]butyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
1-{4-[(3,5-dichlorophenyl)thio]butyl}-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[4-(cyclopentylsulfonyl)butyl]-2-ethyl-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
1-{4-[(3,5-dichlorophenyl)sulfonyl]butyl}-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[4-(cyclohexylthio)butyl]-2-ethyl-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
1-[4-(butylthio)butyl]-2-ethyl-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
1-{4-[(4-chlorophenyl)thio]butyl}-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[4-(butylsulfonyl)butyl]-2-ethyl-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

2-ethyl-1-{4-[(4-fluorophenyl)thio]butyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-{4-[(1-methylethyl)sulfonyl]butyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-ethyl-1-[4-(ethylthio)butyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-ethyl-1-[4-(ethylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
1-[4-(cyclohexylsulfonyl)butyl]-2-ethyl-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-butyl-1-{2-[(1-methylethyl)sulfonyl]ethyl}-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-butyl-1-[2-(phenylsulfonyl)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-butyl-1-{2-[(4-fluorophenyl)sulfonyl]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-{2-[(1,1-dimethylethyl)sulfonyl]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-{2-[(1,1-dimethylethyl)thio]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[2-(propylsulfonyl)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-butyl-1-[2-(propylthio)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-butyl-1-{2-[(2-methylpropyl)sulfonyl]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-{2-[(2-methylpropyl)thio]ethyl}-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[2-(ethylsulfonyl)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-butyl-1-[2-(ethylthio)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;  
2-butyl-1-[2-(methylsulfonyl)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[6-(methylsulfonyl)hexyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[5-(phenylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[5-(methylsulfonyl)pentyl]-2-(trifluoromethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-(2-methoxyethyl)-1-[5-(phenylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-[4-(pyrimidin-2-ylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-[4-(pyrimidin-2-ylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[4-(methylsulfonyl)butyl]-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[5-(methylsulfonyl)pentyl]-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-{4-[(1-methylethyl)sulfonyl]butyl}-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-{4-[(4-fluorophenyl)sulfonyl]butyl}-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine; and

2-methyl-1-{4-[(1,1-dimethylethyl)sulfonyl]butyl}-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

45-48 (canceled)

49 (new) A compound selected from the group consisting of

2-ethyl-1-[2-(methylsulfonyl)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[2-(propylsulfonyl)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

2-butyl-1-[2-(ethylsulfonyl)ethyl]-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

2-methyl-1-[5-(methylsulfonyl)pentyl]-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

or a pharmaceutically acceptable salt thereof.

50-51 (canceled)

52. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of claim 49 that induces cytokine biosynthesis.